Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

3(33.3%)

N/A

3(33.3%)

Phase 2

3(33.3%)

9Total

Phase 1(3)

N/A(3)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06003270Phase 2Recruiting

Biological Effects of Quercetin in COPD Phase II

Role: collaborator

NCT01168739Not ApplicableCompleted

Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response

Role: collaborator

NCT03989271Phase 1Unknown

Biological Effects of Quercetin in COPD

Role: collaborator

NCT02195232Phase 2Completed

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

Role: collaborator

NCT04474626Phase 2Withdrawn

Isoquercetin in Sickle Cell Anemia

Role: collaborator

NCT02446795Phase 1Unknown

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

Role: collaborator

NCT01708278Phase 1Completed

Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)

Role: collaborator

NCT02866448Not ApplicableWithdrawn

Impact of isoQUercetin and Aspirin on Platelet Function

Role: collaborator

NCT01538316Not ApplicableUnknown

Prostate Cancer Prevention Trial With Quercetin and Genistein

Role: collaborator

All 9 trials loaded